Understanding of the antl tory actions of nonsteroidal drugs is incomplete, but these actions are believed to occur in the periphery, without any contribution from the central nervous system. Recent research on the antipyretic antUnflammatory neuropeptide a-melanocytestimulating hormone indicates that it can act centrally to inhibit peripheral inflatlon; this raises the possibility that other agents, such as nonsteroidal antilnflammatory drugs, may have similar activity. In the present research both lysine acetylsalicylate and sodium salicylate inhibited edema, induced in the mouse ear by topical application of picryl chloride, when injected into the lateral cerebral ventricle. This inhibitory activity on a measure of acute flammation was not due to escape of the drugs into the periphery, because systemic iqjection of doses that were effective centrally did not affect The antipyretic action of these common drugs is believed to differ from their antiinflammatory action in that it must occur within the brain (8). However, because (i) a-MSH and antipyretic/antiinflammatory drugs have similar effects; (ii) the drugs, whether given centrally or peripherally, act within the brain to inhibit fever; and (iii) as stated above, central injection of a-MSH inhibits acute inflammation in the periphery, it may be. that NSAIDs likewise act centrally to influence inflammation. To test this idea, NSAIDs were administered i.c.v. to mice with acute cutaneous inflammation induced by local application of picryl chloride.
stimulating hormone indicates that it can act centrally to inhibit peripheral inflatlon; this raises the possibility that other agents, such as nonsteroidal antilnflammatory drugs, may have similar activity. In the present research both lysine acetylsalicylate and sodium salicylate inhibited edema, induced in the mouse ear by topical application of picryl chloride, when injected into the lateral cerebral ventricle. This inhibitory activity on a measure of acute flammation was not due to escape of the drugs into the periphery, because systemic iqjection of doses that were effective centrally did not affect inflammation. In contrast, central admintion of a dose of indomethain-that was antfmmatory when given intraperitoneally did not inhibit peripheral ifmmation. Thus indomethacin apparently lacks the central antiinflammatory action of the salicylates. This observation, plus our inability to demonstrate either an antlinflammator effect of intracerebroventricular dexamethasone, a prostaglandin inhibitor, or a pro-inlammatory influence of prostaglandin E%, suggts that prglandins are not important to central modulation of inflammation. The results indicate that, in addition to having -central-Influences on feverand pain, salicylates can act within the brain to inhibit acute inflammation, in the periphery.
Hypotheses about the mechanisms of action of antiinflammatory drugs have focused on peripheral actions such as inhibition of hydrolytic enzymes, metabolism of arachidonic acid, and migration ofpolymorphonuclear leukocytes, monocytes, and lymphocytes into injured tissue (1) . More recently, local cytokines such as tumor necrosis factor-and interleukin 1 have been linked to-inflammation (2) . Although the central nervous system (CNS} was identified as a possible target for the action of nonsteroidal antiinflammatory drugs (NSAIDs) in pioneering studies (3) , modem reviews of antiinflammatory agents do not mention any influence of the CNS (e.g., refs. 4 and 5). However, recent observations indicate that peripheral acute inflammation characterized by edema can be inhibited by a central action of the neuropeptide a-melanocyte-stimulating hormone (a-MSH; melanotropin); local application of picryl chloride to the mouse ear evoked edema that was inhibited in a dose-dependent fashion by intracerebroventricular (i.c.v.) administration of this peptide (6) . The effect on-edema could not be traced to an a-MSH-induced increase in circulating corticosterone, a glucocorticoid that has marked antiinflammatory activity. a-MSH, like common antipyretic drugs, also reduces fever when given centrally or peripherally (7) .
The antipyretic action of these common drugs is believed to differ from their antiinflammatory action in that it must occur within the brain (8 Each animal was anesthetized with 10%o pentobarbital sodium solution (50 mg/kg; Nembutal; Abbott). Base-line thickness of both ears was measured with a spring-loaded micrometer (Swiss Precision Instruments, Los Angeles). To induce ear edema, a classic sign of acute inflammation, both sides of each ear were coated with 10-jul (44) /l total per mouse)-of 0.5% picryl chloride in acetone (9) . Immediately thereafter, an NSAID, dexamethasone, or prostaglandin E2 (PGE2), dissolved in nonpyrogenic saline (20 IL), or saline alone (20 /ul), was injected directly into a lateral cerebral ventricle of each anesthetized mouse. The general technique has been described previously (10) . The animals were anesthetized again 3 and 6 hr later, and ear swelling was determined by subtracting the base-line thickness from the measurements obtained for each ear at 3 and 6 hr. The differences for the two ears were averaged for the final analysis. The NSAIDs lysine acetylsalicylate (Maggioni-Winthrop, Milan), sodium salicylate (Fisher Scientific), and indomethacin were tested. The salicylates were selected both because of their potent antiinflammatory activity and because they are soluble in water and can therefore be readily injected into the brain. A water-soluble form of indomethacin, sodium indo- (Fig. 1 , F = 10.35, P < 0.0001). Edema was inhibited in a dose-related fashion at 3 hr, with a mean maximum of 41% inhibition after the 100l-1g dose; only this dose remained effective at 6 hr (53% inhibition). The antiinflammatory influence of central lysine acetylsalicylate was not secondary to-escape of the drug into the periphery, because neither the largest effective central dose (100 jg) nor a dose 10-fold greater had any effect on inflammation when given i.p. (Fig. 2) . On the other hand, a systemic dose of 10 mg did inhibit inflammation, perhaps consistent with sufficient penetration ofthe drug into the brain, as suggested from previous research on salicylate distribution in the mouse (11) , and/or with adequate peripheral action of the drug. To learn whether the central antiinflammatory effect is limited to the specific molecular conformation of lysine acetylsalicylate, 100 ug of sodium salicylate was administered both i.c.v. and i.p. (Fig. 3) . Given centrally, this agent likewise inhibited acute inflammation of the ear (F = 38.9, P < 0.0001). The inhibition of edema was approximately 30%o at 3 hr and 44% at 6 hr. As with lysine acetylsalicylate, i.p. administration of the same dose had no influence (F = 3.19, P = 0.89).
To test further the generality of the central action of NSAIDs on acute inflammation, indomethacin was administeredcentrally. A dose of 100Mug had no effect on edema (Fig.   4) . One milligram was not only ineffective, it killed two offive mice in initial tests. When 100 ,ug of indomethacin was given i.p., itdid inhibit the edema (F = 18.1, P < 0.0001). Inhibition was 51% at 3 hr and 42% at 6 hr.
Dexamethasone, a potent synthetic glucocorticoid believed to inhibit inflammation locally, in part by inhibition of arachidonic acid release, was administered in a dose judged to beover 6-fold more effective than a prednisolone dose that had previously been shown, when given i.p., to inhibit inflammation in the mouse ear (9) . Dexamethasone had no inhibitory action on peripheral edema when injected i.c.v. (Fig. 5) . Rather, there was a small but significant increase in ear swelling at 3 hr.
To test the idea raised by the indomethacin and dexamethasone results that central prostaglandins are not important to modulation of peripheral inflammation, PGE2 or saline was injected i.c.v. after picryl chloride treatment in 40 mice. Doses of 0.25, 0.5, and 1.0 Mug (n = 10 for each dose) had no effect on peripheral inflammation (F = 0.4, P = 0.76); the I.C.V.
[. P. (21), believed to be released via activity of nonmyelinated fibers of the sympathetic nervous system. There is recent evidence (22) that plasma extravasation induced in rats by activation of unmyelinated primary afferents, mast cells, or sympathetic postganglionic nerve terminals is significantly reduced by surgical excision of the lumbar sympathetic chain. Plasma extravasation is a major feature of swelling in the mouse ear edema model used in the present experiments. Furthermore, induction of an inflammatory response on one side of the body results in similar changes on the other side (23, 24) ; sciatic neurectomy attenuates the contralateral response. Selective lesions of smalldiameter afferents or of postganglionic sympathetic efferents also retard and attenuate swelling in the uninjured paw (25) , whereas venous ligation does not, ruling out a contribution of hormonal factors. Additional evidence of neurogenic involvement in inflammation are findings that rheumatoid arthritis is often bilateral and that rheumatic disease is often less in paretic limbs (26) .
Given the existence of a neurogenic mechanism of inflammation, how (27) . There has been no attempt to test the effect of PAG or NRM stimulation on acute inflammation per se, but the relation between inflammation and pain in the periphery is strong. It may be that central NSAIDs induce descending inhibitory influences on the spinal cord, dorsal root ganglion, and sympathetic chain to reduce the neurogenic aspect of inflammation, perhaps via inhibition of release of agents such as histamine and substance P, or their precursors, that are known to alter vascular permeability and to cause pain.
The present results reinforce the view that for certain NSAIDs, in addition to their peripheral effects, a CNS action might contribute to their an'tiinflammatory activity. The precise steps through which central salicylates inhibit aspects of acute cutaneous inflammation remain to be elucidated, but it is reasonable to suspect that these drugs act through release of endogenous secondary mediators within the brain. One candidate for such a role as a secondary mediator is a-MSH, a neuropeptide recently shown to inhibit acute peripheral inflammation when administered centrally (6) .
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